Buchumschlag

Long‐term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM‐3 study

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Michael H. Tomasson, Shinsuke Iida, Ruben Niesvizky, Mohamad Mohty, Nizar J. Bahlis, Joaquin Martinez‐Lopez, Guenther Koehne, Paula Rodriguez‐Otero, H. Miles Prince, Andrea Viqueira, Eric Leip, Umberto Conte, Sharon T. Sullivan, Alexander M. Lesokhin
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	HemaSphere
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Prognostic significance of PET/CT for CAR T cell therapy in relapsed/refractory multiple myeloma
von: Patrick Born, et al.
Veröffentlicht: (2025)

Varnimcabtagene autoleucel (ARI‐0001) in relapsed or refractory mantle cell lymphoma
von: Nil Albiol, et al.
Veröffentlicht: (2026)

Optimizing therapy for relapsed/refractory classic Hodgkin lymphoma in the era of PD‐1 blockade
von: Thomas M. Kuczmarski, et al.
Veröffentlicht: (2025)

High‐risk features of early relapse in newly‐diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapy
von: Andrea Manubens, et al.
Veröffentlicht: (2025)

Impact of second autologous stem‐cell transplantation at relapsed multiple myeloma: A French multicentric real‐life study
von: Axel André, et al.
Veröffentlicht: (2024)

Disease‐burden‐adapted immunotherapy protocol for primary refractory or high‐risk relapsed pediatric acute lymphoblastic leukemia
von: Sanaa Khan, et al.
Veröffentlicht: (2024)

Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high‐risk relapsed/refractory Hodgkin lymphoma
von: Matthew Mei, et al.
Veröffentlicht: (2025)

Long‐term immune changes in patients with relapsed/refractory chronic lymphocytic leukemia following treatment with venetoclax plus rituximab
von: Arnon P. Kater, et al.
Veröffentlicht: (2024)

Prognostic significance of immune reconstitution following CD19 CAR T‐cell therapy for relapsed/refractory B‐cell lymphoma
von: Sophia Stock, et al.
Veröffentlicht: (2025)

Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real‐world intention‐to‐treat analysis
von: Maeve A. O'Reilly, et al.
Veröffentlicht: (2024)

Isatuximab in combination with chemotherapy for pediatric patients with relapsed/refractory acute lymphoblastic leukemia or acute myeloid leukemia: The ISAKIDS study
von: André Baruchel, et al.
Veröffentlicht: (2025)

Dynamics of complete responses (CRs) in patients with relapsed or refractory follicular lymphoma (R/R FL) treated with odronextamab in the ELM‐2 study
von: Stefano Luminari, et al.
Veröffentlicht: (2026)

Navigating the evolving management of smoldering multiple myeloma
von: M. Bakri Hammami, et al.
Veröffentlicht: (2026)

Outcomes and prognostic factors in 3306 patients with relapsed/refractory chronic lymphocytic leukemia treated with ibrutinib outside of clinical trials: A nationwide study
von: Gian Matteo Rigolin, et al.
Veröffentlicht: (2024)

The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study
von: Andrew D. Zelenetz, et al.
Veröffentlicht: (2024)

Efficacy and safety of the academic anti‐CD19 chimeric antigen receptor T‐cell product varnimcabtagene autoleucel for the treatment of relapsed/refractory follicular lymphoma
von: Núria Martínez‐Cibrián, et al.
Veröffentlicht: (2025)

Real‐life efficacy and safety of vemurafenib plus rituximab in relapsed or refractory hairy‐cell leukemia: A multicenter Italian retrospective study (HCL‐PG03R)
von: Luca De Carolis, et al.
Veröffentlicht: (2025)

Cell‐free DNA for detection and monitoring of extramedullary AML relapse
von: Henri C. Hupe, et al.
Veröffentlicht: (2025)

Outcomes of patients with relapsed or refractory primary mediastinal B‐cell lymphoma treated with anti‐CD19 CAR‐T cells: CARTHYM, a study from the French national DESCAR‐T registry
von: Jean Galtier, et al.
Veröffentlicht: (2025)

Daratumumab‐based quadruplet for patients with extramedullary multiple myeloma: Results from the Phase II prospective EMN19 study
von: Meral Beksac, et al.
Veröffentlicht: (2026)

High‐risk cytogenetic abnormalities in multiple myeloma: PETHEMA‐GEM experience
von: Veronica González‐Calle, et al.
Veröffentlicht: (2024)

Central nervous system myeloma: Pathogenesis, diagnostic challenges, and practical management strategies
von: Eirini Katodritou, et al.
Veröffentlicht: (2025)

Expression profile of Bcl‐2 family proteins in newly diagnosed multiple myeloma patients
von: Cristina De Ramón, et al.
Veröffentlicht: (2024)

Interferon gamma‐mediated prevention of tumor progression in a mouse model of multiple myeloma
von: Zoltán Kellermayer, et al.
Veröffentlicht: (2024)

Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes
von: Kazimierz Groen, et al.
Veröffentlicht: (2024)

Clonal competition assays identify fitness signatures in cancer progression and resistance in multiple myeloma
von: Larissa Haertle, et al.
Veröffentlicht: (2024)

Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma
von: Juan‐Jose Garces, et al.
Veröffentlicht: (2025)

CDK6 protein expression is associated with disease progression and treatment resistance in multiple myeloma
von: Johannes Steinhart, et al.
Veröffentlicht: (2024)

Current and future role of carfilzomib‐based quadruplet combinations as therapy for newly diagnosed multiple myeloma
von: Ola Landgren, et al.
Veröffentlicht: (2025)

Combined inhibition of CTPS1 and ATR is a metabolic vulnerability in p53‐deficient myeloma cells
von: Romane Durand, et al.
Veröffentlicht: (2024)

Preclinical evaluation of the CD38‐targeting engineered toxin body MT‐0169 against multiple myeloma
von: Wassilis S. C. Bruins, et al.
Veröffentlicht: (2024)

Body composition predicts poor outcomes and reveals immunometabolic dysfunction via single‐cell profiling in anti‐BCMA CAR T‐treated myeloma
von: Thomas C. Wiemers, et al.
Veröffentlicht: (2026)

The evolving pattern of the monoclonal protein improves the IMWG 2/20/20 classification for patients with smoldering multiple myeloma
von: Anna de Daniel, et al.
Veröffentlicht: (2024)

Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet‐treated multiple myeloma without transplant
von: Benjamin A. Derman, et al.
Veröffentlicht: (2025)

Correction to “Prevention and treatment of venous thromboembolism in patients with multiple myeloma: Clinical practice guidelines on behalf of the European Myeloma Network”
Veröffentlicht: (2025)

Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: Results from the prospective, observational CHAGAL study
von: Sonia Morè, et al.
Veröffentlicht: (2025)

Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network
von: Niels W. C. J. van de Donk, et al.
Veröffentlicht: (2025)

Impact of the kinetics of circulating anti‐BCMA CAR‐T cells and normal lymphocytes on the outcome of MM patients
von: Sara Gutiérrez‐Herrero, et al.
Veröffentlicht: (2025)

Genetic evolution and relapse‐associated mutations in adult T‐cell acute lymphoblastic leukemia patients treated in PETHEMA trials
von: Celia González‐Gil, et al.
Veröffentlicht: (2025)

30‐Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis
von: Enrique M. Ocio, et al.
Veröffentlicht: (2024)